Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
View Patent ↗This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin. The compositions may further contain molecules that are not native to botulinum toxin and that bind non-covalently to the botulinum toxin complexes, thereby acting as skin-tropic “adhesion molecules” to improve the ability of the toxin complexes to adhere to and to penetrate the skin epithelium. The compositions have an improved safety profile compared to existing botulinum -containing compositions that are injected subcutaneously. Methods for the use of such compositions are also contemplated by this invention.
1. A method of transdermally administering a botulinum toxin to a subject, the method comprising
topically applying an effective amount of a composition to intact skin in an area in need thereof, the composition comprising
botulinum toxin; and
a sialoprotein adhesion molecule;
wherein the sialoprotein adhesion molecule is present in said composition in an amount from 0.1 ng to 1 mg per unit of botulinum toxin, inclusive; and
wherein the sialoprotein adhesion molecule is selected from the group consisting of bone sialoprotein I and bone sialoprotein II.
2. The method according to claim 1 , wherein the sialoprotein adhesion molecule is bone sialoprotein I.
3. The method according to claim 1 , wherein the sialoprotein adhesion molecule is bone sialoprotein II.
4. A method of treating a condition by transdermal administration of a botulinum toxin to a subject, said method comprising:
topically applying an effective amount of a composition to an area in need thereof, the composition comprising
botulinum toxin; and
a sialoprotein adhesion molecule;
wherein the sialoprotein adhesion molecule is present in said composition in an amount from 0.1 ng to 1 mg per unit of botulinum toxin, inclusive,
wherein the condition is selected from the group consisting of muscular spasm, clinical or subjective hyperhidrosis, acne, pain, clinical or subjective dystonia, hypersecretion, wrinkles, and an immune disorder; and
wherein the sialoprotein adhesion molecule is selected from the group consisting of bone sialoprotein I and bone sialoprotein II.
5. The method according to claim 4 , wherein the sialoprotein adhesion molecule is bone sialoprotein I.
6. The method according to claim 4 , wherein the sialoprotein adhesion molecule is bone sialoprotein II.
7. The method according to claim 4 , wherein the condition is muscular spasm.
8. The method according to claim 4 , wherein the condition is clinical hyperhidrosis.
9. The method according to claim 4 , wherein the condition is subjective hyperhidrosis.
10. The method according to claim 4 , wherein the condition is acne.
11. The method according to claim 4 , wherein the condition is pain.
12. The method according to claim 4 , wherein the condition is clinical dystonia.
13. The method according to claim 4 , wherein the condition is subjective dystonia.
14. The method according to claim 4 , wherein the condition is hypersecretion.
15. The method according to claim 4 , wherein the condition is wrinkles.
16. The method according to claim 4 , wherein the condition is an immune disorder.